Pharmaceutical

Cytokinetics looks to take on BMS’ Camzyos in hypertrophic cardiomyopathy

Cytokinetics plans to file for approval in both the US and Europe for its hypertrophic cardiomyopathy therapy by the end of the year.

May 15, 2024 - 04:00
Cytokinetics looks to take on BMS’ Camzyos in hypertrophic cardiomyopathy
Cytokinetics plans to file for approval in both the US and Europe for its hypertrophic cardiomyopathy therapy by the end of the year.
Read the original article

Tags:

Previous Article

AbbVie makes psychedelic play with $2bn Gilgamesh collaboration

Next Article

AI database to bolster research for GLP1-RAs as precision medicines

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US

Cost of disease-modifying therapies for multiple sclero...

May 20, 2023

Catalent CEO drops FY2023 revenue forecast by $450m after “disappointing” quarter

Catalent CEO drops FY2023 revenue forecast by $450m aft...

May 30, 2023

Opinion: Lessons from Ukraine on protecting mental health during conflict

Opinion: Lessons from Ukraine on protecting mental heal...

Sep 22, 2023